(EYPT) –
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Form 4 EyePoint Pharmaceuticals For: Mar 30 Filed by: Paggiarino Dario A.
-
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
-
EyePoint Pharmaceuticals (EYPT) July 10 and 20 puts active on spread
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
Form 10-K EyePoint Pharmaceuticals For: Dec 31
-
Form 8-K EyePoint Pharmaceuticals For: Mar 07
-
EyePoint Pharmaceuticals (EYPT) Tops Q4 EPS by 16c ; Provides Outlook
-
EyePoint Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Developments
-
Form 4 EyePoint Pharmaceuticals For: Mar 01 Filed by: Ribeiro Ramiro
-
Form 3 EyePoint Pharmaceuticals For: Mar 01 Filed by: Ribeiro Ramiro
-
EyePoint Pharmaceuticals (EYPT) Appoints Ramiro Ribeiro as Chief Medical Officer
-
Form 8-K EyePoint Pharmaceuticals For: Mar 04
-
EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer
-
EyePoint Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on March 7, 2024
-
Form 4 EyePoint Pharmaceuticals For: Feb 27 Filed by: Duker Jay S.
-
EyePoint Pharmaceuticals Announces Participation at Upcoming Investor Conferences
-
Form 4 EyePoint Pharmaceuticals For: Feb 20 Filed by: Duker Jay S.
-
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
-
EyePoint Pharmaceuticals, Inc. (EYPT) PT Raised to $39 at Mizuho Securities
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Form SC 13G EyePoint Pharmaceuticals Filed by: PRICE T ROWE ASSOCIATES INC /MD/
-
Form 4 EyePoint Pharmaceuticals For: Feb 09 Filed by: Lurker Nancy
-
Form 4 EyePoint Pharmaceuticals For: Feb 09 Filed by: Paggiarino Dario A.
-
Form 4 EyePoint Pharmaceuticals For: Feb 09 Filed by: Elston George
-
Form 4 EyePoint Pharmaceuticals For: Feb 09 Filed by: Jones David Scott
-
Form 4 EyePoint Pharmaceuticals For: Feb 09 Filed by: Duker Jay S.
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: ADAGE CAPITAL PARTNERS GP, L.L.C.
-
Form SC 13G/A EyePoint Pharmaceuticals Filed by: FRANKLIN RESOURCES INC
-
Form 4 EyePoint Pharmaceuticals For: Feb 02 Filed by: Jones David Scott
-
EyePoint Pharmaceuticals (EYPT) says subgroup analyses reinforce the highly favorable clinical profile of EYP-1901
-
EyePoint Pharmaceuticals Announces Two Presentations of Topline Data with Additional Subgroup Analyses from the Phase 2 DAVIO 2 Clinical Trial of EYP-1901 for the Treatment of Wet Age-Related Macular
-
Form 144 EyePoint Pharmaceuticals Filed by: Jones David Scott
-
EyePoint Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Form 4 EyePoint Pharmaceuticals For: Jan 26 Filed by: Paggiarino Dario A.
-
Form 4 EyePoint Pharmaceuticals For: Jan 26 Filed by: Jones David Scott
-
Form 4 EyePoint Pharmaceuticals For: Jan 25 Filed by: Paggiarino Dario A.
-
Form 4 EyePoint Pharmaceuticals For: Jan 24 Filed by: Jones David Scott
-
Form 4 EyePoint Pharmaceuticals For: Jan 23 Filed by: Paggiarino Dario A.
-
Form 4 EyePoint Pharmaceuticals For: Jan 23 Filed by: Lurker Nancy
-
Form 4 EyePoint Pharmaceuticals For: Jan 22 Filed by: Jones David Scott
-
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
-
Form 144 EyePoint Pharmaceuticals Filed by: Jones David Scott
-
Form 144 EyePoint Pharmaceuticals Filed by: Lurker Nancy
-
Form 144 EyePoint Pharmaceuticals Filed by: Paggiarino Dario A.
-
Form 144 EyePoint Pharmaceuticals Filed by: Jones David Scott
-
JPMorgan Starts EyePoint Pharmaceuticals, Inc. (EYPT) at Overweight, 'An Eyeful of Opportunities in EYP-1901'
-
Form 4 EyePoint Pharmaceuticals For: Jan 11 Filed by: Ocumension Therapeutics
-
Form 4 EyePoint Pharmaceuticals For: Jan 11 Filed by: Liu Ye
Back to EYPT Stock Lookup
